Eli Lilly looks to expand access to Olumiant across Africa with Eva Pharma licensing deal

Lilly and Eva Pharma enter licensing agreement to commercialize Olumiant across Africa

Eli Lilly and Company (NYSE: LLY) and Eva Pharma have entered into an exclusive licensing agreement to commercialize Olumiant (baricitinib) across Africa. [1] Olumiant is a once-daily oral JAK inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). [2]

The licensing agreement will allow Eva Pharma to register, distribute, and commercialize Olumiant in all 54 African countries

Under the terms of the agreement, Eva Pharma will be responsible for the registration, distribution, and commercialization of Olumiant in all 54 African countries. [1] Lilly will continue to manufacture Olumiant and supply it to Eva Pharma. [3]

The agreement is part of Lilly's commitment to increasing access to its medicines in Africa

The agreement is part of Lilly's commitment to increasing access to its medicines in Africa. [1] Lilly has a long history of working in Africa, and the company is committed to providing innovative medicines to patients in the region. [4]

Eva Pharma is a leading pharmaceutical company in Africa

Eva Pharma is a leading pharmaceutical company in Africa. [5] The company has a strong presence in the region and is well-positioned to commercialize Olumiant. [3]

The licensing agreement is a significant step forward in Lilly's efforts to improve the lives of patients in Africa

The licensing agreement is a significant step forward in Lilly's efforts to improve the lives of patients in Africa. [1] Olumiant is a safe and effective treatment for RA, and the agreement will allow more patients in Africa to access this important medicine. [4]

Conclusion

The licensing agreement between Lilly and Eva Pharma is a positive step forward in the fight against RA in Africa. [1] Olumiant is a safe and effective treatment for RA, and the agreement will allow more patients in Africa to access this important medicine. [4] Lilly is committed to increasing access to its medicines in Africa, and the agreement with Eva Pharma is a significant step forward in this effort. [3]